Company Overview

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small-molecule therapies for the treatment of metabolic and chronic diseases, primarily diabetes and obesity. The company operates within the biotechnology and pharmaceutical research industries and does not currently generate commercial product revenue, relying instead on capital markets and strategic transactions to fund operations.

The company’s core strategy centers on developing differentiated oral alternatives to injectable therapies, particularly in large and underserved metabolic disease markets. vTv Therapeutics was founded in 2000 and has evolved from a broad early-stage drug discovery platform into a more focused clinical-stage organization emphasizing cardiometabolic indications. Its approach emphasizes selective targeting of validated biological pathways using small molecules designed for oral delivery.

Business Operations

vTv Therapeutics’ operations are primarily organized around drug discovery and clinical development, with revenue generation historically limited to collaboration payments and licensing-related income rather than product sales. The company’s lead clinical programs target type 1 diabetes, type 2 diabetes, and obesity, with development activities spanning preclinical research through mid-stage clinical trials.

The company conducts research and development largely through internal scientific teams while also utilizing contract research organizations for clinical trials and manufacturing. vTv Therapeutics holds intellectual property related to its proprietary compounds and has, at various times, entered into licensing or asset sale transactions involving non-core programs. Data inconclusive based on available public sources regarding any active joint ventures or material operating subsidiaries.

Strategic Position & Investments

Strategically, vTv Therapeutics is positioned to address significant unmet needs in metabolic disease through oral therapies that may complement or compete with injectable biologics. Its growth strategy emphasizes advancing its most promising clinical candidates through value-inflection milestones, including clinical trial readouts and potential partnering opportunities.

The company has periodically streamlined its pipeline by divesting or discontinuing programs outside its core focus areas. Its most notable investments are internal, centered on advancing proprietary compounds through clinical development rather than acquiring external businesses. Public disclosures indicate continued exploration of emerging oral metabolic therapies, though specific future commercial strategies remain dependent on clinical outcomes and financing conditions.

Geographic Footprint

vTv Therapeutics is headquartered in the United States, with primary operations based in North Carolina. Its activities are predominantly U.S.-focused, particularly with respect to research, corporate management, and regulatory engagement.

International exposure is limited and generally indirect, occurring through globally conducted clinical trials and relationships with international service providers. The company does not report material physical operations or offices outside North America, and its global influence is primarily tied to the potential international applicability of its therapeutic candidates rather than established commercial infrastructure.

Leadership & Governance

vTv Therapeutics was co-founded by Mac Andrews, a biotechnology entrepreneur, and Paul Sekhri, who continues to play a central role in the company’s leadership. The governance structure follows a traditional public biotechnology model, with a board of directors overseeing strategy, capital allocation, and executive management. Leadership communications consistently emphasize capital discipline, scientific rigor, and focus on high-impact clinical programs.

Key executives include:

• Paul Sekhri – President and Chief Executive Officer
• Mac Andrews – Founder and Chairman of the Board
• Mark T. Heise – Chief Financial Officer
• David Ziegler – Senior Vice President, Operations

The leadership team’s stated strategic vision centers on advancing orally administered therapies that address large, chronic disease markets while maintaining flexibility to partner or out-license assets as appropriate.